Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?

OBJECTIVE To examine autoantibody clusters and their associations with clinical features and organ damage accrual in patients with systemic lupus erythematosus (SLE). METHODS The study group comprised 1,357 consecutive patients with SLE who were recruited to participate in a prospective longitudinal cohort study. In the cohort, 92.6% of the patients were women, the mean +/- SD age of the patients was 41.3 +/- 12.7 years, 55.9% were Caucasian, 39.1% were African American, and 5% were Asian. Seven autoantibodies (anti-double-stranded DNA [anti-dsDNA], anti-Sm, anti-Ro, anti-La, anti-RNP, lupus anticoagulant (LAC), and anticardiolipin antibody [aCL]) were selected for cluster analysis using the K-means cluster analysis procedure. RESULTS Three distinct autoantibody clusters were identified: cluster 1 (anti-Sm and anti-RNP), cluster 2 (anti-dsDNA, anti-Ro, and anti-La), and cluster 3 (anti-dsDNA, LAC, and aCL). Patients in cluster 1 (n = 451), when compared with patients in clusters 2 (n = 470) and 3 (n = 436), had the lowest incidence of proteinuria (39.7%), anemia (52.8%), lymphopenia (33.9%), and thrombocytopenia (13.7%). The incidence of nephrotic syndrome and leukopenia was also lower in cluster 1 than in cluster 2. Cluster 2 had the highest female-to-male ratio (22:1) and the greatest proportion of Asian patients. Among the 3 clusters, cluster 2 had significantly more patients presenting with secondary Sjögren's syndrome (15.7%). Cluster 3, when compared with the other 2 clusters, consisted of more Caucasian and fewer African American patients and was characterized by the highest incidence of arterial thrombosis (17.4%), venous thrombosis (25.7%), and livedo reticularis (31.4%). By using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, the greatest frequency of nephrotic syndrome (8.9%) was observed in patients in cluster 2, whereas cluster 3 patients had the highest percentage of damage due to cerebrovascular accident (12.8%) and venous thrombosis (7.8%). Osteoporotic fracture (11.9%) was also more common in cluster 3 than in cluster 2. CONCLUSION Autoantibody clustering is a valuable tool to differentiate between various subsets of SLE, allowing prediction of subsequent clinical course and organ damage.

[1]  M. Tikly,et al.  Autoantibodies in black South Africans with systemic lupus erythematosus: Spectrum and clinical associations , 2005, Clinical Rheumatology.

[2]  J. Mikdashi,et al.  Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. , 2004, Rheumatology.

[3]  G. Ruiz-Irastorza,et al.  Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus , 2004, Lupus.

[4]  D. Isenberg,et al.  Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[5]  C. Lau,et al.  Damage accrual in southern Chinese patients with systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[6]  C. Gordon,et al.  Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. , 2003, Rheumatology.

[7]  L. Magder,et al.  Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[8]  L. Magder,et al.  Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[9]  D. Alarcón-Segovia,et al.  Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. , 2000, Journal of autoimmunity.

[10]  L. Magder,et al.  Damage in systemic lupus erythematosus and its association with corticosteroids. , 2000, Arthritis and rheumatism.

[11]  N. Bianco,et al.  Cluster analysis of antinuclear autoantibodies in the prognosis of SLE nephropathy: are anti-extractable nuclear antibodies protective? , 2000, Lupus.

[12]  J. Ioannidis,et al.  Risk factors for central nervous system involvement in systemic lupus erythematosus. , 2000, QJM : monthly journal of the Association of Physicians.

[13]  J. Ioannidis,et al.  Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. , 2000, The American journal of medicine.

[14]  C. Gordon,et al.  The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. , 1999, Rheumatology.

[15]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[16]  Caroline Gordon,et al.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. , 1999, Arthritis and rheumatism.

[17]  F. Medina,et al.  Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration , 1998, Lupus.

[18]  D. Isenberg,et al.  Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. , 1997, British journal of rheumatology.

[19]  S. Gutierrez-Ureña,et al.  Autoantibody profile in African-American patients with lupus nephritis , 1996, Lupus.

[20]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[21]  G. Hughes,et al.  Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. , 1995, The American journal of medicine.

[22]  I. Scharrer,et al.  Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.

[23]  P. Limburg,et al.  Prevention of relapses in systemic lupus erythematosus , 1995, The Lancet.

[24]  M. Petri,et al.  One Hundred Anti‐Ro (SS‐A) Antibody Positive Patients: A 10‐Year Follow‐Up , 1995, Medicine.

[25]  S. Studenski,et al.  Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. , 1995, Arthritis and rheumatism.

[26]  J. Nossent,et al.  Course and prognostic value of Systemic Lupus Erythematosus Disease Activity Index in black Caribbean patients. , 1993, Seminars in arthritis and rheumatism.

[27]  G. Hughes,et al.  Systemic Lupus Erythematosus: Clinical and Immunologic Patterns of Disease Expression in a Cohort of 1,000 Patients , 1993 .

[28]  M. Okamura,et al.  Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. , 1993, Annals of the rheumatic diseases.

[29]  M. Petri,et al.  Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. , 1991 .

[30]  C. Kallenberg,et al.  Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. , 1990, Seminars in arthritis and rheumatism.

[31]  P. Limburg,et al.  Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. , 1990, Arthritis and rheumatism.

[32]  S. Studenski,et al.  Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. , 1990, Archives of internal medicine.

[33]  G. Hughes,et al.  Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. , 1989, The American journal of medicine.

[34]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.